Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (6502)	6/7/2002 10:22:52 AM
From: aknahow	Read Replies (1) \| Respond to of 52153

Had expected FDA decision on Amevive to clear the air one way or the other. But BGEN now says it has always said approval is expected at year end or first quarter 2003. So, I no longer think movement in biotech stocks will drift until an August FDA Amevive decision. Year end is too far away of an event to influence the entire sector, until then. Some other seminal event will be needed to cause a rally or wash out decline. Thought it would be final word on Amevive but apparently not.